Showing results (371-380 of 378) with videos related to

Sort By:
Pageof 38
You have reached the last page of results.This site can display upto 378 results.
Cancer Biotherapy & Radiopharmaceuticals|September 15, 2017
Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use 177Lu-DOTA-TATE: The Intricate Radiochemistry AspectsAnupam Mathur, Vrinda Prashant, Navin Sakhare, et al.
Journal of Gastrointestinal Cancer|June 14, 2024
Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine TumorsSaneya A Pandrowala, Deeksha Kapoor, Aditya Kunte, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 15, 2020
One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian settingSandip Basu, Sudipta Chakraborty, Rahul V Parghane, et al.
Frontiers in Endocrinology|November 29, 2023
Association of Cutibacterium acnes with human thyroid cancerVaishakhi Trivedi, Vanita Noronha, Peddagangannagari Sreekanthreddy, et al.
BMC Cancer|October 29, 2025
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Ameya D Puranik, Indraja D Dev, Sushil Yadav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO GuidelineJaydira Del Rivero, Kimberly Perez, Erin B Kennedy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and ParagangliomaAbhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
JCO Oncology Practice|May 9, 2025
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO GuidelineKimberly Perez, Jaydira Del Rivero, Erin B Kennedy, et al.
Pageof 38